Literature DB >> 14043354

STREPTOMYCIN AS AN ANTIVIRAL AGENT: MODE OF ACTION.

T D BROCK, S O WOOLEY.   

Abstract

In host bacteria resistant to the antibiotic, streptomycin inhibits phage replication by inhibiting the process of injection. This effect is competitively reversed by certain divalent cations, polyamines, and streptidine. It is proposed that streptomycin inhibits injection by attaching to the phage DNA while it is still folded within the phage head, and in this way it prevents the unfolding which is essential for the injection process. The reversal agents probably function by displacing the antibiotic from the phage, but they also promote injection themselves.

Entities:  

Keywords:  AGAR; CALCIUM; COLIPHAGES; DNA, VIRAL; EXPERIMENTAL LAB STUDY; MAGNESIUM; SPERMINE; STREPTOCOCCUS; STREPTOMYCIN; VIRUS CULTIVATION

Mesh:

Substances:

Year:  1963        PMID: 14043354     DOI: 10.1126/science.141.3585.1065

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  7 in total

1.  Effect of resistance to chloramphenicol on bacteriophage sensitivity of group A streptococci.

Authors:  P L Friend; H D Slade
Journal:  J Virol       Date:  1967-02       Impact factor: 5.103

2.  Inhibition of the infective activity of bacteriophage f 2 by spermine.

Authors:  J Schindler
Journal:  Experientia       Date:  1965-12-15

3.  Effects of streptomycin and novobiocin on Staphylococcus aureus gene expression.

Authors:  K Nordström; M Lindberg
Journal:  J Bacteriol       Date:  1978-02       Impact factor: 3.490

4.  HOST RANGE OF CERTAIN VIRULENT AND TEMPERATE BACTERIOPHAGES ATTACKING GROUP D STREPTOCOCCI.

Authors:  T D BROCK
Journal:  J Bacteriol       Date:  1964-07       Impact factor: 3.490

5.  Bacteriophage infecting the myxobacterium Chondrococcus columnaris.

Authors:  D T Kingsbury; E J Ordal
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

6.  Aminoglycoside Antibiotics Inhibit Phage Infection by Blocking an Early Step of the Infection Cycle.

Authors:  Larissa Kever; Aël Hardy; Tom Luthe; Max Hünnefeld; Cornelia Gätgens; Lars Milke; Johanna Wiechert; Johannes Wittmann; Cristina Moraru; Jan Marienhagen; Julia Frunzke
Journal:  mBio       Date:  2022-05-04       Impact factor: 7.786

7.  In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19.

Authors:  Bharath Br; Hrishikesh Damle; Shiban Ganju; Latha Damle
Journal:  F1000Res       Date:  2020-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.